Scarica l'app Stockscreener
9.4684
2.03%
0.1884
Dopo l'orario di chiusura:
9.47
0.0016
+0.02%
Precedente Chiudi:
$9.28
Aprire:
$9.58
Volume 24 ore:
2,788
Relative Volume:
0.05
Capitalizzazione di mercato:
$259.34M
Reddito:
-
Utile/perdita netta:
$-102.09M
Rapporto P/E:
-9.0175
EPS:
-1.05
Flusso di cassa netto:
$-108.72M
1 W Prestazione:
-3.31%
1M Prestazione:
+10.61%
6M Prestazione:
+115.19%
1 anno Prestazione:
+93.51%
Intervallo 1D:
$9.4684
$9.76
Intervallo di 1 settimana:
$9.1312
$10.37
Portata 52W:
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
Nome
Dbv Technologies Adr
Settore
Industria
Telefono
33(0)155427878
Indirizzo
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Confronta DBVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.4684 | 253.79M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-29 | Ripresa | Goldman | Sell |
| 2023-01-04 | Aggiornamento | Societe Generale | Hold → Buy |
| 2022-12-16 | Downgrade | Goldman | Neutral → Sell |
| 2022-05-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-09-14 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-01-22 | Downgrade | Societe Generale | Hold → Sell |
| 2020-11-02 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-08-06 | Downgrade | Societe Generale | Buy → Sell |
| 2020-08-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-17 | Downgrade | Stifel | Buy → Hold |
| 2020-01-09 | Aggiornamento | Stifel | Hold → Buy |
| 2019-12-16 | Iniziato | Citigroup | Buy |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Iniziato | Goldman | Buy |
| 2018-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Downgrade | Jefferies | Buy → Hold |
| 2018-12-20 | Downgrade | Stifel | Buy → Hold |
| 2017-10-31 | Aggiornamento | Societe Generale | Sell → Hold |
| 2017-10-24 | Downgrade | Societe Generale | Buy → Sell |
| 2017-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Iniziato | Deutsche Bank | Buy |
| 2017-03-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2016-09-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-03 | Iniziato | Barclays | Overweight |
| 2015-10-23 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Dbv Technologies Adr Borsa (DBVT) Ultime notizie
European ADRs Inch Higher As Drugmakers Shine - Finimize
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire
DBV Technologies Taps Healthcare Veteran as CHRO to Drive Commercial Evolution - Stock Titan
What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional
European Stocks In The US Finish With A Modest Rebound - Finimize
European ADRs Climb As Verona Pharma Leads Gains - Finimize
European ADRs Climb As Sequans Leads The Charge - Finimize
DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India
DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World
European Stocks Climb As ADRs Post Gains - Finimize
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Research Analysts Set Expectations for DBVT Q2 Earnings - Defense World
Lifesci Capital Upgrades DBV Technologies (NASDAQ:DBVT) to Strong-Buy - Defense World
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
DBV Technologies stock holds steady as JMP reiterates $21 price target - Investing.com
Breakthrough Peanut Allergy Treatment Enters Critical Phase 3 Trial for Toddlers as Young as 12 Months - Stock Titan
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why - Defense World
DBV Technologies to Participate in Upcoming EAACI Congress 2025 - The Manila Times
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - GlobeNewswire
DBV Technologies Secures Full Shareholder Support at Annual Meeting: Key Governance Updates - Stock Titan
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - GlobeNewswire
DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote - Stock Titan
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 By Investing.com - Investing.com South Africa
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities - Defense World
European ADRs Rise On S&P Europe Select Index - Finimize
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs Slip As US Index Notes Mixed Gains And Losses - Finimize
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
Dbv Technologies Adr Azioni (DBVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):